Dermorphin vs Livagen
Side-by-side comparison of key properties, dosing, and research.
Recovery & Repair
DermorphinAnti-Aging & Longevity
Livagen- Summary
- Dermorphin is a naturally occurring heptapeptide opioid isolated from the skin of South American phyllomedusine frogs. It is one of the most potent endogenous mu-opioid receptor agonists known, approximately 30-40 times more potent than morphine by weight. Explored for pain management and fatigue modulation.
- Livagen is a dipeptide bioregulator (Lys-Glu) developed by Professor Vladimir Khavinson, tissue-specific for the liver and thymus. It supports hepatocyte function, promotes liver cell regeneration, and modulates immune function via thymic activity. Research suggests benefits in chronic liver disease, hepatic aging, and immune restoration following liver damage.
- Half-Life
- Estimated 30-60 minutes (longer than endorphins due to D-Ala)
- Short (minutes); gene-regulatory effects are sustained
- Admin Route
- Subcutaneous (research), Intrathecal (research), Intranasal (research)
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- Not established for human use; research doses vary widely
- 10 mg per day
- Frequency
- Not established
- Daily for 10–30 days
- Key Benefits
- Potent analgesia superior to morphine on a per-weight basis
- May reduce perception of fatigue in high-intensity activity
- Longer-lasting than endogenous opioids due to D-amino acid substitution
- Research tool for mu-opioid receptor pharmacology
- Potential therapeutic application in refractory pain
- Supports hepatocyte regeneration and liver tissue repair
- Normalizes liver cell protein synthesis
- Immune modulation via thymic activity
- Potential benefits in chronic hepatitis and liver aging
- Anti-aging effects on hepatic tissue
- May support liver recovery after toxic insult or alcohol damage
- Complementary to NAD+ and glutathione in liver health protocols
- Side Effects
- High addiction and dependence potential (mu-opioid agonism)
- Respiratory depression at high doses
- Nausea, vomiting, constipation
- Sedation and cognitive impairment
- +2 more
- Generally well tolerated
- Mild injection site reactions
- No significant hepatotoxic effects reported at standard doses
- Stacks With
- —
- —